Back to dashboard
CommercialCoverageMedium impact

08.00.33u, Trastuzumab (Herceptin®) and Related Biosimilars, Trastuzumab and Hyaluronidase-oysk (Herceptin Hylecta)

Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Days to comply
—

Summary

The policy for Trastuzumab (Herceptin) and related biosimilars has been updated for commercial plans. This affects coverage and billing requirements for this cancer treatment medication commonly used in oncology practices.

Action Required

Action needed
By October 1, 2025: Billing team must review updated Trastuzumab (Herceptin) policy requirements for commercial plans. Update billing protocols and prior authorization processes as specified in the full policy. Verify current coverage criteria and documentation requirements to prevent claim denials.

Related policy hubs